Summary
The AI-generated claims largely align with the FDA label for tadalafil (ED/BPH indication, PDE5 mechanism, key interactions with nitrates, alpha-blockers, and CYP3A modulators, common and serious adverse effects, pharmacokinetics). Some magnesium-specific interaction details and broader non-label alternatives/patents/generic status are not present in the label and are treated as omissions or unsupported claims.
Category Scores
Accurate Statements
Tadalafil is marketed for erectile dysfunction and for symptoms of benign prostatic hyperplasia.
Section 17 (PATIENT COUNSELING INFORMATION) indicates tadalafil is marketed as Cialis for ED and BPH symptoms.
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor.
Section 12.1 (Mechanism of Action) describes tadalafil as a PDE5 inhibitor.
Tadalafil works by increasing blood flow to the penis during sexual stimulation by inhibiting PDE5, which degrades cGMP.
Section 12.1 (Mechanism) describes PDE5 inhibition leading to increased cGMP and vascular effects.
Inhibiting PDE5 allows cGMP to accumulate, leading to relaxation of smooth muscles in penile blood vessels and increased penile blood flow.
Section 12.1 (Mechanism) describes accumulation of cGMP and downstream relaxation.
Common side effects include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion, typically mild and temporary.
Section 6 (Adverse Reactions) lists these as common adverse effects and characterizes them as typically mild/temporary.
Less common but serious adverse effects include sudden vision loss and sudden hearing loss.
Section 5.3 (Visual Loss) and Section 5.4 (Hearing Impairment) describe these events.
An erection lasting longer than four hours (priapism) can occur and requires emergency medical attention.
Section 5.6 (Prolonged Erection) describes priapism and urgent attention.
Tadalafil has a half-life of approximately 17.5 hours, with a window of effectiveness up to about 36 hours after a dose.
Section 12.3 (Pharmacokinetics) provides the half-life and extended window.
Tadalafil should not be used with organic nitrates; coadministration can cause dangerous hypotension.
Section 4.1 (Concomitant Nitrates) states contraindication with nitrates.
Alpha-blockers and PDE5 inhibitors can have additive vasodilatory effects; interactions with doxazosin, alfuzosin, or tamsulosin are noted.
Section 7.2 (Alpha-Blockers) describes additive BP-lowering effects.
CYP3A inhibitors/inducers can increase tadalafil levels in the blood.
Section 7.5 (CYP3A Inhibitors/Inducers) discusses interactions with modulators of CYP3A.
Tadalafil is marketed as Cialis for ED and for BPH, as referenced in patient labeling.
Section 17 (PATIENT COUNSELING INFORMATION) notes the Cialis branding for ED and BPH.
The mechanism describes increasing penile blood flow via PDE5 inhibition and cGMP accumulation leading to erection.
Section 12.1 (Mechanism) details this pharmacodynamic sequence.
Common adverse effects include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion.
Section 6 (Adverse Reactions) lists these specific effects.
These side effects are typically mild and temporary.
Section 6 (Adverse Reactions) describes them as generally mild/temporary.
Unsupported Statements
Magnesium plays a role in many bodily functions, including muscle and nerve function.
Label does not discuss magnesium or its physiological roles.
The specific interaction between tadalafil and magnesium is not extensively detailed in readily available public information.
Label does not discuss magnesium interactions.
Information on the direct interaction of taking magnesium supplements with tadalafil is limited.
Label does not provide magnesium-specific interaction details.
Magnesium is an essential mineral involved in numerous physiological processes.
Label does not discuss magnesium.
It is generally considered safe for most individuals.
Label does not provide a general safety statement about magnesium.
Patients should always provide a comprehensive list of all medications, including over-the-counter drugs and supplements, to their doctor before starting tadalafil.
Label/Counseling cautions exist but do not explicitly require a comprehensive meds list.
Alternatives to tadalafil for treating erectile dysfunction include other PDE5 inhibitors such as sildenafil, vardenafil, and avanafil.
Label does not discuss alternative PDE5 inhibitors.
Other treatment options may involve vacuum erection devices, penile injections, urethral suppositories, or surgical implants.
Label does not enumerate non-pharmacologic ED treatments.
For benign prostatic hyperplasia, other medications and treatment approaches are available.
Label does not enumerate BPH alternatives.
A healthcare provider can recommend the most suitable alternative based on individual health status and needs.
Label does not provide explicit guidance on selecting alternatives.
Contradictions
Important Omissions
Explicit dosing or administration instructions for tadalafil are not provided in the claims.
Importance:
High
Storage and handling details for tadalafil are not covered by the claims.
Importance:
Moderate
Use in specific populations (e.g., pregnancy, pediatric use) details are not covered by the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims align with label's major safety warnings (nitrate contraindication, alpha-blocker and CYP3A interactions, common/serious adverse effects, priapism) with no emergent new safety concerns introduced by the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Include explicit dosing/administration details if evaluating dosage claims, and consider adding a caveat about non-pharmacologic ED treatments and patent/generic status if relevant to the user's use case.